Assertio Therapeutics Stock News

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Assertio Holdings, Inc. has impressive growth rates and an attractive valuation. The company's involvement with an opioid in the past may explain the low valuation.

Companies with strong profitability tend to have more stable earnings and cash flows, which can make them more resilient to market volatility. This article focuses on stocks with a proven track record

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Recently, Zacks.com users have been paying close attention to Assertio (ASRT). This makes it worthwhile to examine what the stock has in store.

Assertio Holdings, Inc. (NASDAQ:ASRT ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Matt Kreps - Darrow Associates, Investor Relations Dan Peisert - President & Chief

Assertio (ASRT) delivered earnings and revenue surprises of 482.61% and 1.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Assertio (ASRT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d

Assertio is a truly impressive turnaround story that is now set to grow, mostly through M&A. The crucial ingredient is the digital-only sales model, which puts acquired drugs on a much lower cost basi

Q4 preliminary results illustrate the best product sales quarter for the past 5 years. Technicals, valuation, and profitability trends all point to rising prices for the stock.

Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Assertio (ASRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.